The impact of perioperative dexmedetomidine infusion on postoperative narcotic use and duration of stay after laparoscopic bariatric surgery.
Dexmedetomidine (Precedex, Hospira, Lake Forest, IL) is an alpha-2 receptor agonist with sedative and analgesic sparing properties. This medication has not been associated with respiratory suppression, despite occasionally high levels of sedation. For 10 months, all patients undergoing a laparoscopic bariatric procedure received a dexmedetomidine infusion 30 min before the anticipated completion of the procedure (n = 34). A control group was comprised of a similar number of patients to have had laparoscopic bariatric surgery in the time period immediately before these 10 months (n = 37). All pathways and discharge criteria were identical for patients in each group. A total of 73 patients were included in this retrospective chart review. Two gastric bypass patients were excluded for complications requiring additional surgery (one bleed and one leak). Gastric bypass patients who received a dexmedetomidine infusion required fewer narcotics (66 vs 130 mg of morphine equivalents) than control patients and met discharge criteria on post-op day (POD) 1 more often (61% discharged POD 1 vs 26% discharged POD 1, p = 0.02). Vital signs and pain scores were similar in all groups. Dexmedetomidine infusion perioperatively is safe and may help to minimize narcotic requirements and decrease duration of stay after laparoscopic bariatric procedures. This may have important patient safety ramifications in a patient population with a high prevalence of obstructive sleep apnea. A well-organized prospective, randomized, double-blinded trial is necessary to confirm the benefits of dexmedetomidine suggested by this study.
Dholakia
Chirag
C
Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Beverstein
Gretchen
G
Garren
Michael
M
Nemergut
Christopher
C
Boncyk
John
J
Gould
Jon C
JC
D020927:Dexmedetomidine / Q000008:administration & dosage*; D005260:Female; D015390:Gastric Bypass; D015391:Gastroplasty; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage*; D007902:Length of Stay; D008297:Male; D009294:Narcotics / Q000008:administration & dosage*; D019990:Perioperative Care; D011184:Postoperative Period; D012189:Retrospective Studies
D006993:Hypnotics and Sedatives; D009294:Narcotics; D020927:Dexmedetomidine
Obes Surg. 2001 Oct;11(5):627-30
11594108
Can J Anaesth. 2006 Jul;53(7):646-52
16803911
Anesthesiology. 2006 May;104(5):1081-93; quiz 1117-8
16645462
Ann Surg. 2005 Oct;242(4):494-8; discussion 498-501
16192809
Anesth Analg. 1997 Nov;85(5):1136-42
9356115
Obes Surg. 2004 Jan;14(1):23-6
14980029
Br J Anaesth. 2003 Jul;91(1):31-9
12821563
J Pharm Pharmacol. 1974 May;26(5):361-3
4152777
Anesth Analg. 2000 Mar;90(3):699-705
10702460
Anesth Analg. 2004 Jan;98(1):153-8, table of contents
14693611
JAMA. 2005 Oct 19;294(15):1909-17
16234497
JAMA. 2002 Oct 9;288(14):1723-7
12365955
Crit Care. 2000;4(5):302-8
11056756
Anesthesiology. 2000 Nov;93(5):1345-9
11046225